VINCERX PHARMA INC (VINC)
US92731L1061 - Common Stock
Friday's after hours session: top gainers and losers
After hours stock analysis on 2024-12-06: top gainers and losers in today's session.
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
Also Exploring Strategic Alternatives to Complement Fundraising Efforts...
Vincerx Pharma Reports Third Quarter 2024 Financial Results
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data...
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the...
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024
VINC stock results show that Vincerx Pharma beat analyst estimates for earnings per share the second quarter of 2024.
Vincerx Pharma Reports Second Quarter 2024 Financial Results
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule...
VINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024
VINC stock results show that Vincerx Pharma missed analyst estimates for earnings per share the first quarter of 2024.
VINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vincerx Pharma (NASDAQ:VINC) just reported results for the first quarter of 202...
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236,...
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering...
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of...
Why Is Laser Photonics (LASE) Stock Up 130% Today?
Laser Photonics stock is rising higher on Tuesday as LASE investors celebrate a new unit order from L3Harris Technologies.
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
Vivos Therapeutics stock is up on Tuesday as VVOS investors react to the company securing full Medicare reimbursement for its OSA device.
Why Is Vincerx Pharma (VINC) Stock Down 64% Today?
Vincerx Pharma stock is falling hard on Tuesday after the company failed to impress VINC shareholders with its latest clinical trial update.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with...
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023
VINC stock results show that Vincerx Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vincerx Pharma (NASDAQ:VINC) just reported results for the fourth quarter of 20...
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a...